引用本文:赵海霞,吴玉梅,孙 辉,周清华.老年人慢性缺血性肾病患者血清MMP-9及TIMP-1的检测及意义[J].中国临床新医学,2010,3(4):318-321.
【打印本页】   【下载PDF全文】   查看/发表评论  【EndNote】   【RefMan】   【BibTex】
←前一篇|后一篇→ 过刊浏览    高级检索
本文已被:浏览 1448次   下载 924 本文二维码信息
码上扫一扫!
分享到: 微信 更多
老年人慢性缺血性肾病患者血清MMP-9及TIMP-1的检测及意义
赵海霞,吴玉梅,孙 辉,周清华
250062 济南,山东省医学科学院(赵海霞);272111 济宁,山东省医学科学院附属济宁市第一人民医院(吴玉梅,孙 辉,周清华)
摘要:
[摘要] 目的 通过观察老年人慢性缺血性肾病患者血清基质金属蛋白酶-9(matrix metalloproteinase-9,MMP-9)及其抑制物金属蛋白酶组织抑制因子-1(tissue inhibitor of matrixmetalloproteinase-1,TIMP-1)水平的变化,探讨其在慢性缺血性肾病发病机理中的可能作用及意义。方法 用双抗体夹心ELISA法检测30例老年慢性缺血性肾病患者及22例对照组血清中MMP-9及TIMP-1的水平,并分析两者与血清总胆固醇及肌酐的相关性。结果 慢性缺血性肾病组血清MMP-9和TIMP-1的水平分别为(346.9±14.3)ng/ml、(112.9±10.5)ng/ml,显著高于对照组血清两者的水平(91.6±7.5)ng/ml、(57.4±3.9)ng/ml,结果差异有统计学意义(P<0.01);MMP-9、TIMP-1水平与总胆固醇水平呈明显正相关(r=0.7231,r=0.6415,P均<0.05),与血清肌酐无相关性。结论 MMP-9和TIMP-1参与了慢性缺血性肾病的发病机理,可能是肾缺血损伤的一个独立危险因素。
关键词:  基质金属蛋白酶-9  金属蛋白酶组织抑制因子-1  慢性缺血性肾病
DOI:10.3969/j.issn.1674-3806.2010.04.07
分类号:R 692.3
基金项目:
The significance of determination of serum MMP-9 and TIMP-1 levels in elderly patients with chronic ischemic nephropathy
ZHAO Hai-xia, WU Yu-mei, SUN Hui, et al.
Shandong Academy of Medical Sciences,Jinan 250062,China
Abstract:
[Abstract] Objective To investigate the serum levels of matrix metalloproteinase-9(MMP-9) and its specific inhibitor matrixmetalloproteinase-1(TIMP-1) in elderly patients with chronic ischemic nephropathy and their potential significance in pathogenesis. Methods Serum MMP-9 and TIMP-1 levels were measured with ELISA in 30 patients with chronic ischemic nephropathy and 22 subjects in control group and the correlation with serum lipids and creatinine to be analyzed. Results The serum MMP-9 and TIMP-1 level (346.9±14.3; 112.9±10.5)ng/ml in the nephropathy group were significantly higher than those in controls (91.6±7.5; 57.4±3.9)ng/ml (P<0.01); the serum MMP-9 and TIMP-1 content ware positively correlated with serum total cholesterol(r=0.7231, r=0.6415, P<0.01), but uncorrelated with creatinine. Conclusion MMP-9 and TIMP-1 may be involved in the pathogenesis of chronic ischemic nephropathy and may be the indenpent risk factor in the progression of ischemic nephropathy.
Key words:  Matrix metalloproteinase-9  Tissue inhibitor of matrixmetalloproteinase-1  Chronic ischemic nephropathy